Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
about
Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cellsCerebrovascular dilation via selective targeting of the cholane steroid-recognition site in the BK channel β1-subunit by a novel nonsteroidal agentIleal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat.Proteomics for the discovery of nuclear bile acid receptor FXR targetsTargets for current pharmacologic therapy in cholesterol gallstone disease.Calcium- and voltage-gated potassium (BK) channel activators in the 5β-cholanic acid-3α-ol analogue series with modifications in the lateral chainNutrigenomic analysis of the protective effects of bilberry anthocyanin-rich extract in apo E-deficient mice.Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modificationsTherapy of gallstone disease: What it was, what it is, what it will bePresent and future therapeutic strategies in non-alcoholic fatty liver disease.Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes.FXR signaling in metabolic disease.The farnesoid X receptor regulates transcription of 3beta-hydroxysteroid dehydrogenase type 2 in human adrenal cells.Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts.Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells.Epigenomic regulation of bile acid metabolism: emerging role of transcriptional cofactors.The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease.Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha.Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.The second transmembrane domain of the large conductance, voltage- and calcium-gated potassium channel beta(1) subunit is a lithocholate sensor.Compound and compositions as TGR5 agonists: WO2012082947.The farnesoid X receptor negatively regulates osteoclastogenesis in bone remodeling and pathological bone loss.Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis.
P2860
Q28571177-DC0BA0F3-95F6-4249-831D-79C8FB41708FQ28572738-6265A518-3D40-4186-B435-4EDE736948AEQ30494837-B4964F47-DEA5-4085-8437-2AA4B792E01CQ33856588-18FE5E22-066C-4A1C-AACA-3132A8E6B6ABQ34041538-43F0461E-D150-4063-929A-6B4FED288782Q34322207-2E2079E5-653B-48AC-ADE4-2BFA057507A8Q34338682-D621FCE3-E1D5-412A-A2BC-EDAB075AF822Q34694229-A3576614-FD4B-4953-B8BD-873A533EA0C3Q35948819-2D0B1BD0-AF87-42AD-BA2A-B57E3513D1EBQ36936358-42A8E084-A341-482F-838B-3F6ADF038F6DQ36973016-1BEA0A83-5651-4BAD-A6E6-3B0F2D92511CQ37006382-26A0C8FC-7CA3-43F3-89E6-F6AF1A6894D9Q37184702-18DB2F9F-DEBF-4916-8772-3647BA0BE599Q37462634-7D0D743F-6094-4CC6-84E7-719842A4E31BQ37728687-1F3D1A47-C589-463A-BEFC-2D5FBCB3FA3CQ38009566-A0875A8F-47AF-4282-B704-3B7043FA5B9BQ38044907-60E97CEF-B4EB-4159-BFC3-2BBBCE3CF286Q38787044-0250C284-02B3-4A19-BB57-35AB2893BBE4Q39881956-818A2F05-6E82-4F39-86F4-91BCDA341061Q40017845-9CC9D7C5-B261-405F-A6A0-D25B267A3E2AQ43458051-9E221849-3AB5-4A9B-89DA-BF783441A95CQ45006336-1D2BBCB8-DF97-4BBC-A3C8-36A2A83CC2C0Q53284274-290665FE-7D87-4C3F-B8D0-33506B44ADCC
P2860
Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
@ast
Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
@en
type
label
Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
@ast
Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
@en
prefLabel
Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
@ast
Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
@en
P2860
P1433
P1476
Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
@en
P2093
Antonio Moschetta
Salvatore Modica
P2860
P304
P356
10.1016/J.FEBSLET.2006.07.082
P407
P577
2006-08-08T00:00:00Z